Tocilizumab for rheumatoid arthritis (Q24234126)

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Patterns of disability related to joint involvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Comparison of knowledge and psychological well-being between patients with a short disease duration (< or = 1 year) and patients with more established rheumatoid arthritis (> or = 10 years duration).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Infliximab for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Etanercept for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Rheumatoid arthritis. Treatment of early disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Measurement of patient outcome in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Quality of life in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Rituximab for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Abatacept for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Anakinra for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Adalimumab for treating rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Tocilizumab: the first interleukin-6-receptor inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Tocilizumab for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

Anti–interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2

A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331.PUB2